Asthma Drug Could Fight Aggressive Cancers
But according to a fascinating new study from Northwestern Medicine, this common asthma drug might have a highly unexpected second act: helping the body fight off some of the most aggressive and hard-to-treat forms of cancer.
Published in the prestigious journal Nature Cancer, the research reveals exactly how certain tumors manipulate our immune system to survive—and how an existing asthma medication can effectively short-circuit that process. Let’s dive into the science behind this discovery, why it matters, and how it could reshape the future of immunotherapy.
The Problem: When Immunotherapy Hits a Wall
To understand why this discovery is so significant, we first have to look at how we currently treat cancer. Over the last decade, immunotherapy has revolutionized oncology. Instead of just poisoning cancer cells with chemotherapy, immunotherapy empowers the patient's own immune system to recognize and destroy the tumors.
For many patients, it has been a miracle. But for others, it simply doesn't work.
Certain aggressive cancers—like triple-negative breast cancer (TNBC)—are notoriously difficult to treat. TNBC is a type of breast cancer that lacks the three most common receptors (estrogen, progesterone, and the HER2 protein) that doctors usually target with hormone therapies. Because of this, oncologists often have to rely on broader, less targeted treatments.
When doctors try to use immunotherapy on TNBC and similar aggressive tumors, the tumors often deploy a brilliant, albeit sinister, defense mechanism. They create a "cold" tumor microenvironment. In simple terms, the tumor surrounds itself with a biological shield that prevents the immune system's attacker cells (like T-cells) from getting inside and doing their job.
The Hijacked Immune System
How exactly does a tumor build this shield? The Northwestern Medicine team, led by Dr. Bin Zhang, the Johanna Dobe Professor of Cancer Immunology, discovered that tumors are essentially brainwashing our own cells.
The researchers focused on a specific type of white blood cell called neutrophils. Normally, neutrophils are the immune system's first responders, rushing to the site of cuts and infections to fight off bacteria. But tumors release chemical signals that hijack these neutrophils, drawing them into the tumor microenvironment and transforming them into immunosuppressive guards. Instead of fighting the cancer, these hijacked neutrophils actively suppress the rest of the immune system, allowing the tumor to grow unchecked.
The million-dollar question for Dr. Zhang’s team was: How do we stop the tumor from brainwashing the neutrophils?
The CysLTR1 Switch: A Shared Link with Asthma
Through extensive research involving human cells, massive cancer patient datasets, and mouse models, the scientists pinpointed the exact molecule responsible for this hijacking process. It’s a receptor called CysLTR1 (Cysteinyl leukotriene receptor 1).
If that name sounds familiar to a pulmonologist, it’s because CysLTR1 is a major player in asthma. When you have an asthma attack, molecules called leukotrienes bind to the CysLTR1 receptor in your lungs, causing inflammation, swelling, and mucus production.
Dr. Zhang’s team discovered that tumors exploit this exact same receptor to manipulate neutrophils. CysLTR1 acts as an on/off switch. When the switch is flipped on, the neutrophils become immune-suppressing traitors.
This is where the asthma drug comes in. Medications like montelukast were specifically designed decades ago to block the CysLTR1 receptor to stop asthma attacks. The Northwestern researchers realized that if the drug blocks the receptor in the lungs, it should theoretically block it in the tumor microenvironment, too.
Turning Traitors Into Allies
When the researchers tested CysLTR1-blocking drugs on mouse models with aggressive cancers—including melanoma, ovarian, colon, prostate, and triple-negative breast cancer—the results were remarkable.
By blocking the CysLTR1 pathway, the tumors could no longer hijack the neutrophils. But the most insightful part of the study wasn't just that the drug stopped the bad behavior; it actually reprogrammed the cells.
If you simply eliminate all neutrophils from a patient's body, you leave them incredibly vulnerable to deadly infections. Instead of wiping them out, blocking CysLTR1 retrained these abundant white blood cells to do their original job.
- Tumor growth slowed down.
- Survival rates improved.
- Immunotherapy started working again, even in tumors that had previously become completely resistant to treatment.
“Importantly, instead of simply removing these harmful white blood cells, we were able to reprogram them into cells that support immune attack,” explained Dr. Zhang. “That means we’re not just targeting the cancer, we’re re-training one type of abundant immune cells in the body to fight the tumor again.”
Why Drug Repurposing is a Game-Changer
In the world of medical research, discovering a new biological pathway is only half the battle. Usually, developing a brand-new drug to target that pathway takes 10 to 15 years and billions of dollars, with no guarantee that the drug will be safe for humans.
This is why drug repurposing—finding new uses for existing, FDA-approved medications—is one of the most exciting trends in modern medicine. Because montelukast is already on pharmacy shelves, we already have decades of data proving it is generally safe for human consumption, and we already know its side-effect profile.
The advantages of this approach are massive:
- Speed to Trial: Researchers can skip Phase 1 safety trials and move much faster into testing the drug's efficacy in cancer patients.
- Cost-Effectiveness: Generic versions of asthma drugs are incredibly cheap to produce compared to novel, designer cancer therapeutics.
- Accessibility: If proven effective, the drug is already integrated into the global pharmaceutical supply chain, meaning it could be deployed to patients worldwide almost immediately.
Looking Ahead: From the Lab to the Clinic
The human data analyzed in the study strongly supports the lab findings. When the team looked at public cancer datasets, they found that patients who naturally had higher CysLTR1 activity tended to have much lower survival rates and poorer responses to immunotherapy across multiple types of cancer.
While these preclinical findings are incredibly promising, it is important to remember that cancer patients shouldn't start raiding their medicine cabinets for asthma pills just yet. The next critical step is conducting carefully designed clinical trials to see exactly how this translates to human oncology wards.
Dr. Zhang and his team are currently working to confirm this mechanism in patients and figure out exactly who will benefit the most. They also need to optimize the dosing—the amount of the drug needed to treat an asthma attack might be different from the amount needed to reprogram the immune system against a tumor.
Ultimately, this research serves as a brilliant reminder of how interconnected the human body is. A pathway that causes wheezing and coughing in the lungs is the very same pathway a breast cancer tumor uses to hide from the immune system. By looking at old drugs through a new lens, science is finding innovative ways to give our immune system the backup it needs to win the fight.
Comments
Post a Comment